Takeda Pharmaceutical Co Ltd Oncology Business Investor and Analyst Seminar Transcript
Good afternoon. Thank you very much for your participation in the conference call for seminar on oncology business and its oncology products and disease in Japan. My name Ayako Iwamuro from Takeda Investor Relations.
Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings.
Please also refer to the important notice on Page 2 of the presentation.
And now please let me introduce today's presenters and panel. Takafumi Horii, Head of Japan Oncology Business Unit; Dr. Kei Hiraoka, Medical Director; Dr. Jumpei Soeda, Head of Japan Medical Affairs; Dr. Akiko Kimura, Senior Medical Director; and Yukari Nishikata, Head of Oncology Therapeutic Area Unit.
First, we'd like
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
